New-onset diabetes in COVID-19 and clinical outcomes: A systematic review and meta-analysis

作     者：Dhan Bahadur Shrestha Pravash Budhathoki Sumit Raut Sugat Adhikari Prinska Ghimire Sabin Thapaliya Ali A Rabaan Bibodh Jung Karki 

作者机构：Department of Internal MedicineMount Sinai HospitalChicagoIL 60608United States Department of Internal MedicineBronxCare Health SystemBronxNY 10457United States Department of Emergency MedicineKathmandu Medical CollegeKathmandu 44600Nepal Department of Internal MedicineNishtar Medical UniversityMultan 59330Pakistan Department of Internal MedicineTribhuvan UniversityKathmandu 44600Nepal Department of Internal MedicineTribhuvan University Teaching HospitalKathmandu 44600Nepal Molecular Diagnostic LaboratoryJohns Hopkins Aramco HealthcareDhahran 34465Saudi Arabia Department of Public Health&NutritionThe University of HaripurHaripur 22620Pakistan Division of Infectious DiseasesUniversity of LouisvilleLouisvilleKY 40292United States 

出 版 物：《World Journal of Virology》 (世界病毒学杂志)

年 卷 期：2021年第10卷第5期

页      面：275-287页

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Acute respiratory distress syndrome COVID-19 Diabetes mellitus Hyperglycemia Mortality 

摘      要：BACKGROUND Diabetes mellitus(DM)is associated with adverse clinical outcomes and high mortality in patients with coronavirus disease 2019(COVID-19).The relationship between diabetes and COVID-19 is known to be *** To analyze the rate of new-onset diabetes in COVID-19 patients and compare the clinical outcomes of new-onset diabetes,pre-existing diabetes,hyperglycemic,and non-diabetes among COVID-19 *** We used the Meta-analysis of Observational Studies in Epidemiology statement for the present *** databases were searched for all peerreviewed articles published until November 6,*** were screened using Covidence and data *** analysis was done using comprehensive *** the 128 studies detected after thorough database searching,seven were included in the quantitative *** proportion was reported with 95%confidence interval(CI)and heterogeneity was assessed using *** Analysis showed that 19.70%(CI:10.93-32.91)of COVID-19 patients had associated DM,and 25.23%(CI:19.07-32.58)had associated *** overall mortality rate was 15.36%(CI:12.57-18.68)of all COVID-19 cases,irrespective of their DM *** mortality rate was 9.26%among non-diabetic patients,10.59%among patients with COVID-19 associated hyperglycemia,16.03%among known DM patients,and 24.96%among COVID-19 associated DM *** overall occurrence of adverse events was 20.52%(CI:14.21-28.70)among COVID-19 patients in the included studies,15.29%among non-diabetic patients,20.41%among patients with COVID-19 associated hyperglycemia,20.69%among known DM patients,and 45.85%among new-onset *** showed an increasing rate of mortality among new hyperglycemic patients,known diabetics,and new-onset DM patients in comparison to those without *** A significantly higher rate of new onset DM and hyperglycemia was *** mortality rates and adverse events were seen in patients with